The primary objective of the study is to investigate whether carbohydrate co-ingestion augments the in vivo postprandial muscle protein synthetic response after protein ingestion and whether this response is differs between young and elderly…
ID
Source
Brief title
Condition
- Other condition
- Glucose metabolism disorders (incl diabetes mellitus)
Synonym
Health condition
spiermetabolisme
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Muscle protein synthesis rate, expressed as fractional synthetic rate (FSR).
Secondary outcome
Rate of protein digestion and absorption, whole body protein balance and
microvascular perfusion and diameter.
Background summary
Age related muscle loss (sarcopenia) is assumed to be related to the impaired
postprandial muscle protein synthetic response to protein and/or amino acid
administration in the elderly vs the young. Co-ingestion of carbohydrate
increases post-prandial insulin secretion. Increased insulin secretion affects
skeletal muscle blood flow and may therefore affect substrate availability and
postprandial muscle protein synthesis. However, it is unclear whether the
response to the combined intake of protein and carbohydrates is different in
elderly compared to young subjects.
Hypothesis: Adding carbohydrate to a bolus of protein represents an effective
strategy to overcome the impaired postprandial muscle protein synthesis in the
elderly.
Study objective
The primary objective of the study is to investigate whether carbohydrate
co-ingestion augments the in vivo postprandial muscle protein synthetic
response after protein ingestion and whether this response is differs between
young and elderly subjects. The secondary objective of the study is to assess
the effect of carbohydrate co-ingestion on insulin levels and microvascular
perfusion in young and elderly subjects.
Study design
Double-blind, placebo controlled, parallel, human intervention study.
Intervention
The intervention consists of a single test day during which the subjects will
receive a drink containing 20 gram intrinsically labelled casein with or
without 75 gram carbohydrates. In addition, continuous intravenous tracer
infusions of labeled amino acids will be administered. During the test day 18
plasma samples and 4 muscle biopsies are collected over a period of 8* h.
Furthermore, muscle skeletal blood flow will be estimated using sidestream
darkfield imaging (SDF) in sublingual position.
Study burden and risks
The risks involved in participating in this experiment are minimal. Insertion
of the catheters in a vein is comparable to a normal blood draw and the only
risk is a small local hematoma. This is the same for the muscle biopsies.
Muscle biopsies will be taken through a small (5 mm) incision, following local
anesthetics of the skin and muscle fascia, and will heal completely. Muscle
biopsies will only be obtained by an experienced physician. The test beverages
contain intrinsically labeled dietary protein and carbohydrate which is safe
for human consumption and have been used in previous studies (MEC 06-3-064, MEC
07-3-086, MEC 09-3-078.3). The labeled, non-radioactive amino acids tracers
that will be infused intravenously are produced according to GMP standards and
are completely safe.
postbus 616
6200 MD Maastricht
NL
postbus 616
6200 MD Maastricht
NL
Listed location countries
Age
Inclusion criteria
24 healthy, young male subjects (18-30 y)
24 healthy, elderly male subjects (70-85 y)
Exclusion criteria
• Diabetes
• Obesity (BMI > 30 kg/m2)
• All co-morbidities interacting with mobility and muscle metabolism (e.g. arthrosis, arthritis, spasticity/rigidity, all neurological disorders).
• Hypertension (according to WHO criteria)
• Use of anticoagulants, blood diseases, allergy for lidocain
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL36726.068.11 |